BAYZED HEALTH (02609) surged over 8% during trading, reaching an intraday high of HK$7.13 and setting a new record since listing. As of press time, the stock was up 8.68% to HK$7.14 with a turnover of HK$16.5458 million.

On the news front, BAYZED HEALTH plans to convene a board meeting on August 28 to consider and approve its interim results.

Previously, BAYZED HEALTH collaborated with Peking University Third Hospital and other renowned tertiary hospitals nationwide to formulate the "Cancer Rehabilitation Expert Consensus (2025)," which was successfully published in the authoritative domestic academic journal "Chinese Journal of Clinicians."

According to BAYZED HEALTH's announcement, cancer rehabilitation has become a crucial component in improving patients' quality of life, reducing treatment side effects, and promoting functional recovery. Based on the latest global research and clinical experience, this consensus clarifies the applicable population and objectives for cancer rehabilitation, proposing systematic assessment standards and scientifically feasible "five major prescriptions" rehabilitation strategies.

The consensus emphasizes that cancer rehabilitation should encompass pre-treatment prehabilitation, rehabilitation intervention during treatment, and long-term rehabilitation. Multidisciplinary teams (MDT) should play a core role in cancer rehabilitation.

BAYZED HEALTH is a major cancer medical group in China primarily engaged in investment and provision of medical-related services. As of the last practicable date, the group operates and manages eight hospitals in Beijing, Tianjin, Shanxi Province, Anhui Province, and Henan Province through direct equity ownership in six private for-profit hospitals and management rights in two private non-profit hospitals, focusing on providing comprehensive cancer medical services throughout the entire treatment cycle.